Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 17;12(8):1173.
doi: 10.3390/cells12081173.

Can Epigenetics Predict Drug Efficiency in Mental Disorders?

Gil Ben David  1 , Yam Amir  2 , Randa Salalha  1 , Lital Sharvit  2 , Gal Richter-Levin  1   3   4 , Gil Atzmon  2
Affiliations
Review

Can Epigenetics Predict Drug Efficiency in Mental Disorders?

Gil Ben David et al. Cells. .

Abstract

Psychiatric disorders affect millions of individuals and their families worldwide, and the costs to society are substantial and are expected to rise due to a lack of effective treatments. Personalized medicine-customized treatment tailored to the individual-offers a solution. Although most mental diseases are influenced by genetic and environmental factors, finding genetic biomarkers that predict treatment efficacy has been challenging. This review highlights the potential of epigenetics as a tool for predicting treatment efficacy and personalizing medicine for psychiatric disorders. We examine previous studies that have attempted to predict treatment efficacy through epigenetics, provide an experimental model, and note the potential challenges at each stage. While the field is still in its infancy, epigenetics holds promise as a predictive tool by examining individual patients' epigenetic profiles in conjunction with other indicators. However, further research is needed, including additional studies, replication, validation, and application beyond clinical settings.

Keywords: epigenetics; personalized medicine; psychiatric disorders.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Scheme 1
Scheme 1
Schematic diagram of literature review.
Figure 1
Figure 1
Distribution of reviewed papers by psychiatric disorder: a pie chart illustrating the number of articles included in this review that discuss each specific mental health condition.
Figure 2
Figure 2
Overview of the proposed experimental design for epigenetic personalized medicine drug discovery, highlighting key stages and considerations.
See this image and copyright information in PMC

References

    1. Chan I.S., Ginsburg G.S. Personalized Medicine: Progress and Promise. Annu. Rev. Genom. Hum. Genet. 2011;12:217–244. doi: 10.1146/annurev-genom-082410-101446. - DOI - PubMed
    1. Vogel F. Ergebnisse der Inneren Medizin und Kinderheilkunde. Springer; Berlin/Heidelberg, Germany: 1959. Moderne probleme der humangenetik; pp. 52–125. - DOI
    1. Visscher P.M., Wray N.R., Zhang Q., Sklar P., McCarthy M.I., Brown M.A., Yang J. 10 Years of GWAS Discovery: Biology, Function, and Translation. Am. J. Hum. Genet. 2017;101:5–22. doi: 10.1016/j.ajhg.2017.06.005. - DOI - PMC - PubMed
    1. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: The past, present and future. Trends Pharmacol. Sci. 2004;25:193–200. doi: 10.1016/j.tips.2004.02.007. - DOI - PubMed
    1. Ivanov M., Barragan I., Ingelman-Sundberg M. Epigenetic mechanisms of importance for drug treatment. Trends Pharmacol. Sci. 2014;35:384–396. doi: 10.1016/j.tips.2014.05.004. - DOI - PubMed

Substances